News
ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy
Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.
Saturday 7 February 2026
